Alliance Revenue (Tables)

9 Months Ended

Sep. 30, 2019

Schedule of accompanying statements of operations and comprehensive loss


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2019		2018		2019		2018
Out-license arrangement (1)	$	—	$	—	$	1,447	$	—
GSK collaboration (2)		—		141		—		424
Vivelix collaboration (3)		—		—		—		56
Other (4)		—		4		1		83
Total Alliance revenue	$	—	$	145	$	1,448	$	563

(1)

Revenue recognized in connection with the Licensee Agreement, as more fully described in Note 9.

(2)

Revenue recognized in connection with the GSK Agreement, as more fully described in Note 9.

(3)

Revenue recognized in connection with the Vivelix Agreement, as more fully described in Note 9.

For all periods presented, revenue recognized relates to collaborations which are not material to the Company’s current operations nor expected to be material in the future, including reimbursements by licensees of costs associated with patent maintenance.